Profound Medical
PROF | NASDAQ
$7.34
-$0.08 (-1.08%)
At close: Nov 16, 2026, 4:00 PM ET
$7.20
-$0.14 (-1.91%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Profound Medical Company Profile
Company profile explainedCompany Profile
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Key Executives
| Name | Position |
|---|---|
| Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer |
| Mathieu Burtnyk | Chief Technology Officer |
| Matthew Sobczyk | Interim Chief Financial Officer |
| Levant Tinaz | Software Developer |
| Richard R. Fabian | President |
| Stephen Kilmer | Investor Relations |
| Thomas Tamberrino | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 09, 2026 | 8-K | Current Report |
| Oct 07, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
Profound Medical
| Country | Canada |
| IPO Date | Oct 29, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Arun Swarup Menawat |
Contact Details
2400 Skymark Avenue Mississauga,
ON L4W 5K5 Canada
Stock Details
| Ticker Symbol | PROF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628808 |
| CUSIP Number | 74319B502 |
| ISIN Number | CA74319B5027 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove PROF